Thirumalaisamy P. Velavan
Thirumalaisamy P. Velavan
Professor, Akademischer Oberrat -University of Tübingen/VG-CARE
Verified email at - Homepage
Cited by
Cited by
The COVID‐19 epidemic
TP Velavan, CG Meyer
Tropical medicine & international health 25 (3), 278, 2020
Mild versus severe COVID-19: Laboratory markers
TP Velavan, CG Meyer
International Journal of Infectious Diseases 95, 304-307, 2020
Swarm learning for decentralized and confidential clinical machine learning
S Warnat-Herresthal, H Schultze, KL Shastry, S Manamohan, ...
Nature 594 (7862), 265-270, 2021
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ...
The Lancet Infectious Diseases 16 (4), e47-e63, 2016
Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible
LA Nikolai, CG Meyer, PG Kremsner, TP Velavan
International Journal of Infectious Diseases 100, 112-116, 2020
A global metagenomic map of urban microbiomes and antimicrobial resistance
D Danko, D Bezdan, EE Afshin, S Ahsanuddin, C Bhattacharya, DJ Butler, ...
Cell 184 (13), 3376-3393. e17, 2021
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B. 1.1. 529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine …
E Petersen, F Ntoumi, DS Hui, A Abubakar, LD Kramer, C Obiero, ...
International Journal of Infectious Diseases 114, 268-272, 2022
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
B Krämer, R Knoll, L Bonaguro, M ToVinh, J Raabe, ...
Immunity 54 (11), 2650-2669. e14, 2021
Host genetic factors determining COVID-19 susceptibility and severity
TP Velavan, SR Pallerla, J Rüter, Y Augustin, PG Kremsner, S Krishna, ...
EBioMedicine 72, 2021
Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment
KR Chng, C Li, D Bertrand, AHQ Ng, JS Kwah, HM Low, C Tong, ...
Nature medicine 26 (6), 941-951, 2020
Parasite infection, carcinogenesis and human malignancy
H Van Tong, PJ Brindley, CG Meyer, TP Velavan
EBioMedicine 15, 12-23, 2017
Monkeypox 2022 outbreak: an update
TP Velavan, CG Meyer
Trop Med Int Health 27 (7), 604-605, 2022
Occult hepatitis B virus infection in Nigerian blood donors and hepatitis B virus transmission risks
OO Oluyinka, HV Tong, SY Bui Tien, AH Fagbami, O Adekanle, ...
PloS one 10 (7), e0131912, 2015
Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia
SK Mekonnen, A Aseffa, N Berhe, T Teklehaymanot, RM Clouse, T Gebru, ...
Malaria journal 13, 1-9, 2014
2019-nCoV in context: lessons learned?
RA Kock, WB Karesh, F Veas, TP Velavan, D Simons, LEG Mboera, O Dar, ...
The Lancet Planetary Health 4 (3), e87-e88, 2020
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance
H Tegally, JE San, M Cotten, M Moir, B Tegomoh, G Mboowa, DP Martin, ...
Science 378 (6615), eabq5358, 2022
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
P Kremsner, P Mann, J Bosch, R Fendel, JJ Gabor, A Kreidenweiss, ...
MedRxiv, 2020.11. 09.20228551, 2020
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
PG Kremsner, P Mann, A Kroidl, I Leroux-Roels, C Schindler, JJ Gabor, ...
Wiener Klinische Wochenschrift 133 (17-18), 931-941, 2021
Antimicrobial resistance preparedness in sub-Saharan African countries
L Elton, MJ Thomason, J Tembo, TP Velavan, SR Pallerla, LB Arruda, ...
Antimicrobial Resistance & Infection Control 9, 1-11, 2020
Different population histories of the Mundari-and Mon-Khmer-speaking Austro-Asiatic tribes inferred from the mtDNA 9-bp deletion/insertion polymorphism in Indian populations
K Thangaraj, V Sridhar, T Kivisild, AG Reddy, G Chaubey, VK Singh, ...
Human genetics 116 (6), 507-517, 2005
The system can't perform the operation now. Try again later.
Articles 1–20